重组腺病毒介导的FLT3配体和阿霉素联合治疗小鼠肝癌

目的:将重组腺病毒介导的FLT3配体(FLT3 ligand,FL)与阿霉素(adriamycin,ADM)联合治疗小鼠肝癌,探索基因治疗和化疗相结合治疗肿瘤的新方法。方法:构建携带鼠FL的重组腺病毒载体(AdmFL),单独用其或ADM以及两者联用对实验性肝癌小鼠进行治疗,观察抗肿瘤效果。结果:(1)FL+ADM组小鼠肝癌生长抑制率最大值为56.5％,明显高于ADM组和FL组的27.5％和26.6％(P<0.01);(2)FL+ADM组小鼠早期死亡率为8.3％,明显低于ADM组的37.5％(P<0.01);FL十ADM组小鼠长期生存率为86.4％,明显高于ADM组和FL组的50.0％和41.5％(P<0.01)。结论:(1)FL和ADM治疗小鼠肝癌具有协同作用,FL可显著增强化疗效果;(2)FL能明显降低化疗不良反应。

Treatment of hepatoma in mice by adenovirus-mediated FLT3-ligand combined with adriamycin

Objective: To study the effects of adenovirus-mediated FLT3-ligand and/or adriamycin(ADM) on hepatoma in mice and to explore a new way for hepatoma gene therapy combined with chemotherapy. Methods: The recombinant aden-ovirus vector carrying murine FLT3 ligand (AdmFL) was constructed, AdmFL and/or ADM were injected into the tumor-bearing mice. Their effects on the growth of the tumor and the survival rate of the mice were observed. Results: (1)In FL + ADM group,the hepatoma cell suppression percentage was 56. 5% , while the percentage in ADM group and FL group were 27. 5% and 26. 6%(F<0. 01) respectively; (2) In FL + ADM group,the early death rate was 8. 3%,while the rate in ADM group was 37. 5% ; in FL + ADM group,the survival percentage of mice was 86. 4% , while the percentage in ADM group and FL group were 50% and 41. 5%(P<0. 01) respectively. Conclusion: FL can significantly enhance the effeciency of ADM chemotherapy, and relieve the toxic effects of ADM chemotherapy.